Table 1.
Baseline characteristics of individuals with 3 months of continuous GLP-1 use for intention-to-treat analyses (n=78,076).
| Characteristics | Total (n=78,076) |
Continuous users (n=48,956) |
Discontinuous Users (n=29,120) |
SMD |
|---|---|---|---|---|
| Age (mean, standard deviation) | 54.3 (±13.5) | 54.2 (±13.4) | 54.4 (±13.6) | 0.019 |
| Sex, % | 0.020 | |||
| Female | 64.3% | 64.7% | 63.7% | |
| Male | 35.7% | 35.3% | 36.3% | |
| Race, % | ||||
| White | 65.2% | 66.6% | 62.8% | −0.080 |
| Black or African American | 20.1% | 19.0% | 21.8% | 0.070 |
| Asian | 3.1% | 3.2% | 3.0% | −0.010 |
| Native Hawaiian or Other Pacific Islander | 0.8% | 0.8% | 0.9% | 0.010 |
| American Indian or Alaska Native | 0.5% | 0.5% | 0.5% | −0.005 |
| Other race | 4.0% | 3.8% | 4.3% | 0.024 |
| Unknown | 6.3% | 6.0% | 6.7% | 0.028 |
| Ethnicity, % | ||||
| Hispanic or Latino | 10.9% | 11.4% | 10.1% | −0.043 |
| Not Hispanic or Latino | 78.2% | 79.7% | 75.6% | −0.099 |
| Unknown | 10.9% | 8.9% | 14.3% | 0.170 |
| Marital status, % | ||||
| Married | 36.5% | 36.1% | 37.2% | 0.022 |
| Single | 25.0% | 24.6% | 25.8% | 0.029 |
| Unknown | 38.5% | 39.3% | 37.0% | −0.048 |
| Regional location, % | ||||
| Northeast | 12.5% | 10.7% | 15.6% | 0.146 |
| Midwest | 27.0% | 27.6% | 25.9% | −0.040 |
| South | 46.4% | 47.5% | 44.6% | −0.058 |
| West | 14.1% | 14.2% | 13.9% | −0.009 |
| CCI (mean, standard deviation) | 2.6 (±3.0) | 2.7 (±3.1) | 2.4 (±2.8) | −0.100 |
| Diabetes, % | 65.8% | 65.2% | 66.7% | 0.032 |
| Medication, % | ||||
| Metformin | 44.4% | 45.8% | 42.0% | −0.077 |
| Sulfonylureas | 17.8% | 18.6% | 16.6% | −0.050 |
| DPP-4 inhibitors | 11.8% | 12.4% | 10.9% | −0.046 |
| SGLT2 inhibitors | 11.4% | 11.4% | 11.4% | −0.000 |
| Insulin | 30.6% | 30.6% | 30.5% | −0.002 |
CCI Charlson Comorbidity Index; SMD standardized mean difference